{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"18"}]}],"title":"Participants who received rescue treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"82"}]}],"title":"Participants who did not receive rescue treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Percentage of participants initiating new ITP medication, an increased dose of concomitant ITP medication from baseline, platelet transfusion, or splenectomy.","groups":[{"description":"Matching placebo tablets taken once a day","id":"OG000","title":"Placebo"},{"description":"Eltrombopag 50 mg oral tablets taken once a day (QD)","id":"OG001","title":"Eltrombopag 50 mg QD"}],"paramType":"NUMBER","populationDescription":"All participants randomized to receive placebo or eltrombopag treatment","reportingStatus":"POSTED","timeFrame":"Anytime from Day 1 to Week 26","title":"Percentage of Participants Initiating Rescue Treatment On-therapy","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}